FDA Approves Pfizer's Aromasin for Adjuvant Treatment of Early Breast Cancer in Postmenopausal Women
5th Oct 2005, 22:50 GMT
New Indication Offers Breast Cancer Patients an Advanced Treatment Regimen
FDA Approves Pfizer's Aromasin for Adjuvant Treatment of Early Breast Cancer in Postmenopausal Women related news:
- Market Pulse: Pfizer gets FDA ok for Aromasin as adjuvant treatment — Operations-Related News from StratCenter.com
- FDA Approves New Use for Breast Cancer Drug — WebMD Health Headlines
- FDA Approves Pfizer Request To Market Breast Cancer Drug ... — Pfizer
- Pfizer Cancer Drug Gets Wider Approval — Operations-Related News from StratCenter.com
- FDA lässt Pfizer-Krebsmedikament Aromasin für neue Anwendung zu — Finanztreff.de / BRANCHEN
- Hartford gives break to cancer patients — SacBee -- Business News
- October Is Breast Cancer Awareness Month — Breast Cancer Chronicles
- Breast cancer drug move gives hope to UK patients — Rednova News - Health
- Microarray technology could help predict patient response to adjuvant therapy for breast cancer — EurekAlert! - Cancer
- Breast cancer patients in new hope — the Mail online | Health news
Latest news from Radiology News from StratCenter.com:
- Genzyme increasing R&D presence in San Antonio area
- Eisai Breaks Ground for New Oncology Facility in Research Triangle Park
- Ashok Gupta, MD Joins the Physician Team at Desert Radiologists
- AMICAS Offers Free PACS Webinar for RSNA Attendees
- Enrollment Completed Utilizing Cytori's Adipose-Derived Stem Cell Technology for Treatment of Breast Cancer Complications
- Groundbreaking for Cancer Center on Premier Healh Campus - Middletown
- BSD Medical Sends Message of Hope at Largest Conference of US Radiation Oncologists
- Volcano to Offer 7.5M Shares
- Nautilus Biotech and Creabilis Therapeutics Achieve Technical Milestone in Collaboration to Improve HMGB1 Box A for the Treatment of Rage- and HMGB1-Related Pathologies.
- Adherex Reports Q3 2006 Financial Results